Quantitative Multiplexed Immunohistochemistry Assays for Exploring CAR Modified T Cells and Checkpoint Inhibitors in Lymphoma Trials
Thai H. Tran(Navidea Biopharmaceuticals (United States)), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Catherine Tribouley, Shabnam Tangri(Navidea Biopharmaceuticals (United States)), Hummel Jennifer(Novartis (United States)), Krupa Scott(Novartis (United States)), Sadik H. Kassim(Danaher (United States)), Shyun-Shyun Lee(Novartis (United States)), Reshma Singh, Shawn Cogan(Novartis Foundation), Jelveh Lameh(Lineage Cell Therapeutics (United States))
Cited by 2
Related Papers
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Antibody validation
|BioTechniques|2010|601
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Linear Motif Atlas for Phosphorylation-Dependent Signaling
|Science Signaling|2008|465
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
|New England Journal of Medicine|2025|272